Adoptive T Regulatory Cell Therapy for Tolerance Induction.
There is a clear need to develop strategies to induce tolerance without the need of chronic immunosuppression in transplant recipient and in patients with autoimmunity. Adoptive T regulatory cell (Treg) therapy offers the potential of long-lasting protection. However, based on results of clinical trials so far withex vivoexpanded autologous Tregsin type 1 diabetic (T1D) patients, it seems unlikely that single immunotherapy with Treginfusion without immunomodulation regimens that promote stable donor Tregengraftment and persistence would afford truly significant clinical benefit. Combination therapies could provide improved outcomes with consideration of the fundamental factors required for Treggeneration, homeostasis, and function to promote long-term donor Tregpersistence to provoke beneficial therapeutic outcomes.
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136.
Cecilia
C
Cabello-Kindelan
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136.
Shane
S
Mackey
Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136 ; Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136.
Allison L
AL
Bayer
IL-2; T regulatory cells; T-cells; tolerance; transplantation